Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan

Executive Summary

AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.

You may also be interested in...



AbbVie Says “V” Is For V-Shaped Recovery

The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.

AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

Pharma Dealmaker Saunders Includes Wellness Space In Acquisition Group’s Investment Targets

Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel